Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Pallavi Agarwal

Internal Medicine Tulsa, OK Medical Doctor

NPI 1831249812 CMS profile 1155944

3336 E 32Nd St, Tulsa, OK 74135

Open in the dashboard

General payments

$3,785

204 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Pallavi Agarwal of Tulsa, OK is reported in the CMS Open Payments database as having received $3,785 across 204 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 86th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $496 27
2024 General $509 26
2023 General $567 26
2022 General $419 24
2021 General $666 41
2020 General $436 28
2019 General $692 32

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Pallavi Agarwal
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Pallavi Agarwal were reported at $496. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Pallavi Agarwal Internal Medicine median Middle half National median
2019 $692 $159 $48–$570 $163
2020 $436 $119 $33–$402 $114
2021 $666 $135 $37–$521 $132
2022 $419 $141 $42–$496 $149
2023 $567 $149 $45–$519 $160
2024 $509 $154 $47–$537 $164
2025 $496 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Janssen Pharmaceuticals, Inc $700 30 payments
  2. Lilly USA, LLC $512 33 payments
  3. Boehringer Ingelheim Pharmaceuticals, Inc. $456 26 payments
  4. AbbVie, Inc. $205 12 payments
  5. Corium, Inc. $200 5 payments
  6. GlaxoSmithKline, LLC. $197 13 payments
  7. Novo Nordisk Inc $173 10 payments
  8. Pfizer Inc. $143 7 payments
  9. Biogen, Inc. $130 7 payments
  10. Horizon Therapeutics plc $116 7 payments
  11. Other $954 54 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,785 204 payments
Products named General payments · program years 2019–2025
  1. XARELTO $489 25 payments
  2. JARDIANCE Diabetes $313 19 payments
  3. INVOKANA $238 9 payments
  4. MOUNJARO $178 11 payments
  5. Azstarys $126 1 payment
  6. TRELEGY ELLIPTA $121 8 payments
  7. KRYSTEXXA $116 7 payments
  8. KISUNLA $110 6 payments
  9. JARDIANCE Diabetes $110 8 payments
  10. ADUHELM $94 5 payments
  11. Other $2,440 141 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 47 drugs

Part D claims

1,670

Median for Internal Medicine: 777

Drug cost

$127,578

Median for Internal Medicine: $73,373

Branded share of claims

14.3%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Jardiance Empagliflozin Brand 41 $47,740
Ozempic Semaglutide Brand 12 $19,295
Eliquis Apixaban Brand 25 $17,560
Mounjaro Tirzepatide Brand 11 $11,412
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 13 $9,118
Atorvastatin Calcium Generic 137 $2,765
Losartan Potassium Generic 94 $1,593
Amlodipine Besylate Generic 131 $1,283
Lisinopril Generic 126 $1,145
Levothyroxine Sodium Generic 102 $1,131

The 10 drugs with the highest cost, of 47 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 18 billing codes

Paid by Medicare

$35,222

Medicare's payments for the services billed

Medicare patients

205

Average age 74

Services billed

392

135 women, 70 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 44%
Diabetes 41%
Ischemic heart disease 40%
Chronic kidney disease 36%
Heart failure 33%
Atrial fibrillation 28%
Depression 28%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 12 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
OFEV
  • Boehringer Ingelheim Pharmaceuticals, Inc. $85
$85 — —
SPRAVATO
  • Janssen Pharmaceuticals, Inc $63
$63 — —
GEMTESA
  • Sumitomo Pharma America, Inc. $56
$56 — —
LOREEV XR
  • Almatica Pharma LLC $55
$55 — —
KISUNLA
  • Lilly USA, LLC $36
$36 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 12 in the dashboard with a free account

Records

204 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Oklahoma

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record